Project valuation in the pharmaceutical industry: A comparison of least-squares Monte Carlo real option valuation and conventional approaches

R and D Management

Volumn 38, Issue 5, 2008, Pages 520-537

  Willigers, Bart J A ^a   Hansen, Thomas L ^b,c  

^a Palantir Economic Solutions   (United Kingdom)

^b Ecatrisk A/s   (Denmark)

^c Department of International Economics and Management   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 54349106187     PISSN: 00336807     EISSN: 14679310     Source Type: Journal    
DOI: 10.1111/j.1467-9310.2008.00530.x     Document Type: Article

References (26)

1. Adams, C.P. Brantner, V.V. (2006) Estimating the cost of new drug development: is it really $802 Million? Health Affairs, 25, 420 428.
2. Ardner, R. Levinthal, D.A. (2004) What is not a real option: considering boundaries for the application of real options to business strategy. Academy of Management Review, 29, 1, 74 85.
3. Bahuguna, V. (2000) The Myth of Option Pricing. New Jersey : Bogart Delafield Ferrier, Available at).
4. Belsey, M.J., Harris, L.M., Das, R.R. Chertkow, J. (2006) Biosimilars: initial excitement gives way to reality. Nature Reviews Drug Discovery, 5, 535 536.
5. Black, F. Scholes, M. (1973) The pricing of options and corporate liabilities. Journal of Political Economy, 81, 637 654.
6. Copeland, T. Antikarov, V. (2000) Real Options - A Practioner's Guide, Texere, New York, NY.
7. Coy, P. (1999) Exploiting uncertainty, the "real option" revolution in decision making. Businessweek online, June 7, 1999.
8. Dickson, M. Gagnon, J.P. (2004) Key factors in the rising cost of new drug discovery and development. Nature reviews Drug Discovery, 3, 417 429.
9. DiMasi, J.A., Grabowski, H.G. Vernon, J. (2004) R&D costs and returns by therapeutic category. Drug Information Journal, 38, 211 223.
10. DiMasi, J.A., Hansen, R.W. Grabowski, H.G. (2003) The price of innovation: new estimates of drug development costs. Journal of Health Economics, 22, 151 185.
11. DiMasi, J.A., Hansen, R.W., Grabowski, H.G. Lasagna, L. (1991) Cost of innovation in the pharmaceutical industry. Journal of Health Economics, 10, 107 142.
12. Dixit, A.K. Pindyck, R.S. (1994) Investment Under Uncertainty. Princeton, NJ : Princeton University Press.
13. Geske, R. (1979) The valuation of compound options. Journal of Financial Economics, 7, 63 81.
14. Grabowski, H. Vernon, J. (1990) A new look at the returns and risks to pharmaceutical R&D. Management Science, 36, 804 821.
15. Grabowski, H. Vernon, J. (1996) Longer patents for increased generic competition in the US: the Waxman - Hatch act after one decade. PharmacoEconomics, 10, S2, 110 123.
16. Hansen, R.W. (1979) The pharmaceutical development process: estimates of current development costs and times and the effects of regulatory changes. In : Chien, R.I. (Ed.), Issues in Pharmaceutical Economics, Lexington Books, Lexington, MA, pp. 151 187.
17. Hartmann, M. Hassan, A. (2006) Application of real options analysis for pharmaceutical R&D project valuation - empirical results from a survey. Research Policy, 35, 343 354.
18. Kling, J. (1998) From hypertension, to angina to Viagra. Modern Drug Discovery, 1, 31 38.
19. Kola, I. Landis, J. (2004) Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery, 3, 711 716.
20. LNF (Läkemedelsförmånsnämnden) (2006) Available at
21. Merton, R.F. (1973) Theory of rational option pricing. Bell Journal of Economics and Management Sciences, 4, 141 183.
22. Myers, S.C. (1984) Financial theory and financial strategy. Interfaces, 14, 126 137.
23. Newton, D.P., Paxson, D. Widdicks, M. (2004) Real R&D options. International Journal of Management Reviews, 5-6, 113 130.
24. Nichols, N. (1994) Scientific management at Merck: an interview with CFO Judy Lewent. Havard Business Review, 72, 89 99.
25. Schwartz, E.S. (2004) Patents and R&D as real options. Economic Notes, 33, 23 54.
26. Sick, G. (1989) Capital Budgeting With Real Options. Monograph Series, Finance and Economics, New York University: Salomon Brothers Center.